BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 16059
Title: Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome
Reviewer's code: 02860798
Reviewer's country: Austria
Science editor: Jing Yu
Date sent for review: 2014-12-25 09:46
Date reviewed: 2015-02-14 19:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In the article "Resolution of NASH by rosuvastatin monotherapy in patients with metabolic syndrome" the authors showed that 12month therapy with rosuvastatin reduced NASH and metabolic syndrome. The reviewer thinks this finding is of particular interest, however it would strenghten the findings if the authors add more information about serum parameters not only showing transaminases. Please add data about serum levels of inflammatory cytokines, free fatty acids, triglycerides and total cholesterol. Reduced inflammation after therapy should also be shown at histological level via F4/80 and/or CD11b staining. Reduced lipid accumulation should be confirmed via oil red o staining.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 16059
Title: Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome
Reviewer's code: 03022543
Reviewer's country: China
Science editor: Jing Yu
Date sent for review: 2014-12-25 09:46
Date reviewed: 2015-01-22 10:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In this manuscript, Kargiotis and his colleague tried to study the effect of rosuvastatin monotherapy on NASH. They found rosuvastatin monotherapy could ameliorate biopsy proven NASH and resolve MetS within 12 months. The study is intriguing and provides the new insight in the effect of rosuvastatin monotherapy on NASH. The results are also interesting and promising. Specific comments: Figure 2: What is the P value for ALT, AST, GGT, ALP. Is there a statistically significant difference?